Secondary Logo

Journal Logo

Review Article


Mecott, Gabriel A.*†; Al-Mousawi, Ahmed M.*†; Gauglitz, Gerd G.*†; Herndon, David N.*†; Jeschke, Marc G.*†

Author Information
doi: 10.1097/SHK.0b013e3181af0494
  • Free



Burns are considered one of the most severe forms of trauma (1), with a severity, length, and magnitude unique to these patients (2). More than 500,000 burn injuries occur annually in the United States, resulting in approximately 20,000 acute admissions to burn centers (3). Severely burned patients typically experience a systemic response, including inflammation, increased metabolism, alteration of cardiac and immune function, and hyperglycemia (4).

Stress-induced hyperglycemia (SIH) was observed more than 100 years ago, being first described by Claude Bernard as "diabète traumatique" during hemorrhagic shock (5, 6) and has been also named "diabetes of critical illness" (7) and "burn stress pseudodiabetes" (8). Stress-induced hyperglycemia has been defined as plasma glucose levels more than 200 mg/mL in nondiabetic patients occurring due to injury (9, 10), although it has also been characterized in the range more than 200 mg/dL (9-11) to more than 240 mg/dL (4, 12) in different institutions. It has been observed after severe burns, trauma, myocardial infarction, stroke, or surgery (5, 6, 13-15).

Hyperglycemia is an almost universal finding among patients suffering major burn injury. For many years, this condition was expectantly managed and considered as a normal and desired response (16-19). However, this nontreatment paradigm has recently shifted toward intervention and aggressive treatment of hyperglycemia in an attempt to improve survival and to reduce complication rates (17).

The studies of Van den Berghe et al. (20-22) reported improved survival and decreased morbidity in critically ill patients by maintaining blood glucose levels at or less than 110 mg/dL through the use of intensive insulin regimens. After these studies, tight glycemic control has become a perceived standard of care in critical illness (7), although concern has also risen regarding hypoglycemic events with this type of therapy (22, 23), especially when glucose is monitored with point-of-care glucometers (24).

Seventy-three percent of the verified burn centers of the American Burn Association have presently implemented intensive insulin practices using target upper limit glucose levels in the range of less than 120 mg/dL in most of these units (24). However, when searching for the impact of tight glucose control on morbidity and mortality, most of the available literature about SIH describes mixed populations, where burned patients represent a small percentage of the studied patients when included and leads to difficulty in evaluating the true benefit of reduced plasma glucose levels in this specific patient population.

The aim of this review is to investigate both the pathophysiology and the effects of hyperglycemia on burned patients as well as to describe current therapeutic modalities and their outcomes in an evidence-based fashion in an attempt to clarify whether there is sufficient evidence that anti-hyperglycemic treatment is beneficial and the glucose range that should be aimed for in these patients.


The excess presence of any substance can generally be explained by three conditions: excess of production, reduced clearance (intake or excretion), or presence of both these conditions (Fig. 1). Hyperglycemia in severely burned patients results from a similar set of factors. Burned patients exhibit increased gluconeogenesis and glycogenolysis (increase of glucose production) as well as insulin resistance, leading to decreased glucose uptake and reduced clearance. The underlying mechanisms are not entirely defined, but multiple studies have indicated that SIH is associated with excessive release of catecholamines, cytokines, hormones, and acute phase proteins (10, 14).

Fig. 1
Fig. 1:
Determination of plasma glucose concentration. A, Plasma glucose levels are determined by production/external load and uptake of glucose from peripheral tissues. B, An increase in production or load, a decrease in uptake, or both, lead to increased plasma glucose levels.

Increased glucose production

The metabolic changes in burns occur in two different phases: the initial shock or the "ebb" phase, present in the first 5 days, and the subsequent "flow" phase or the hypermetabolic phase of injury (5, 16, 17, 25). During the ebb phase, activation of the sympathoadrenal and the hypothalamopituitary-adrenal axis occurs, leading to increased plasma levels of catecholamines, glucocorticoids, and cytokines (26). This results in a significant increase of total glucose (27), but mass flow of glucose to peripheral tissue is only slightly altered (16). In the subsequent hypermetabolic flow phase of injury, mass flow of glucose to peripheral tissues increases, directed by sympathetic stimulation (16). Significant impairment of hepatic function is observed in these patients (28), but hepatic gluconeogenesis via Cori and alanine cycles is increased (10, 16, 25). A study in rodents has suggested that burn-related hyperglycemia arises from glycogen breakdown and gluconeogenesis (29), and similar findings were later described by Wolfe et al. (30) in humans. Genes encoding for gluconeogenesis are known to be up-regulated as early as 6 h after burn injury (31), whereas clinically, peak glucose levels are observed between the second and the fourth day after burn (4, 5, 32).

In addition to stress signals, various hormonal changes contribute to hyperglycemia in burned patients and are listed below:

  • a) Epinephrine: elevated in burn patients (33, 34), increasing gluconeogenesis (skeletal muscle and hepatic); also causes insulin resistance by altering postreceptor signaling (10) and increasing lipolysis (10, 14).
  • b) Norepinephrine: increases glucose production mainly by gluconeogenesis via glycerol production (lipolysis) and to a lesser extent than epinephrine by increasing glycogenolysis (10, 14, 33).
  • c) Glucagon: known to stimulate glucose production by increasing hepatic gluconeogenesis and glycogenolysis (5, 10, 14, 35-37). Jahoor et al. (38) found that in severely burned patients, hyperglucagonemia stimulates increased glucose production and that selective lowering of glucagon normalized glucose kinetics (10).
  • d) Cortisol and growth hormone: sustain gluconeogenesis and impair insulin signaling (5, 10). Cortisol promotes hyperglycemia, which is more intense and potentiated when elevated in combination with other counterregulatory hormones (which oppose and counteract the action of insulin) such as catecholamines (14, 17, 39).
  • e) Proinflammatory cytokines: IL-8 and monocyte chemotactic protein 1 (4) especially contribute to postburn hyperglycemia by enhancing the release of the abovementioned stress hormones and by altering insulin receptor signaling (40-42).

As can be seen, SIH is multifactorial and involves a complex cascade leading to increased hepatic output of glucose, which can be increased by approximately 50% in comparison to healthy controls, whereas clearance is similar (10). Evidence also indicates that all insulin-counteracting hormones (epinephrine, glucagon, hydrocortisone, and growth hormone) are involved in stimulating SIH and insulin resistance (43-45).

Reduced glucose clearance

Under physiological conditions, once glucose is released, it can be used by insulin-independent tissues, for example, in the brain, by erythrocytes, or by insulin-dependent glucose uptake in other tissues such as muscle or liver (46, 47). In insulin-dependant tissues, insulin binds to the α subunit on the extracellular portion of its receptor, inducing autophosphorylation of the β unit (48), leading to conformational changes and phosphorylation of insulin receptor substrate 1 at a tyrosine residue, which in turn leads to activation of the phosphatidylinositol 3-kinase/AKT pathway (5). In key insulin-dependent tissues, such as muscle, fat, and liver, this will lead to plasma membrane localization of glucose transporter insulin-responsive glucose transporter 4 (GLUT) (specifically and reversibly up-regulated by insulin (27)), permitting glucose uptake (10, 49) (Fig. 2). Other effects of insulin include activation of glycogen synthesis (50), lipid synthesis (51), inhibition of lipolysis (52), and lipocyte apoptosis (53), thus decreasing glucose plasma levels.

Fig. 2
Fig. 2:
Glucose uptake. Insulin-independent tissues (e.g. erythrocytes) do not require insulin for glucose uptake. Insulin-dependent tissues require binding of insulin to its receptor to activate insulin signaling. This leads to expression of the GLUT-4 transporter, permitting glucose uptake and further oxidation by mitochondria.

The actions of insulin normally cause a switch from catabolic breakdown and a state of gluconeogenesis and glucose release to anabolism and a state of glucose uptake with inhibition of gluconeogenesis. Such anabolic effects are typically not seen after severe burns, where catabolic breakdown predominates. Burn patients typically present with insulin resistance and increased proteolysis, associated with increased hepatic gluconeogenesis and muscle protein catabolism (4, 10, 54-56). These features lead to loss of lean body mass and profound muscle wasting, with consequent muscle weakness, delayed mobilization, impairment of cough reflexes, and prolonged mechanical ventilation, all of which may contribute to increased mortality in these patients (5).

Glucose clearance is diminished in burned patients as insulin-mediated uptake has been shown to be impaired when compared with normal patients (57, 58). Additional factors contributing to impaired glucose clearance include altered insulin signaling (59-61), down-regulation of genes encoding for glucose-6-phosphatase transport protein 1 gene, and GLUT-4 (31). Up-regulation of the renin-angiotensin system has also been associated with insulin resistance (62). A study of 212 severely burned children in our institution revealed that nonfasted serum glucose levels markedly increase during the acute phase postburn to 170 to 180 mg/dL, despite concurrent raised levels of insulin. This implies the presence of insulin resistance, as seen by the observation of hyperglycemia in combination with elevated insulin levels (4).

Our knowledge of the role of cellular organelles in insulin resistance has continued to expand: the endoplasmic reticulum, under conditions of cellular stress, phosphorylates the inositol requiring protein 1 (63), which in turn activates c-Jun N-terminal kinase, thus leading to impaired receptor signaling by blocking tyrosine phosphorylation of the insulin receptor substrate 1 (64-66), features that have been observed in burn patients (5, 67, 68). Several studies have found c-Jun N-terminal kinase to be activated on specific stimuli, including the presence of a number of cytokines, including IL-6, IL-8, monocyte chemotactic protein 1, and TNF-α (5, 10), all of which have been found to be raised under conditions known to be linked with hyperglycemia, such as obesity, diabetes mellitus, and stress (69-72). The endoplasmic reticulum is not the only organelle known to be associated with SIH, as mitochondria are also believed to play an important role in the development SIH. Mitochondrial oxidation of free fatty acids generates acetyl-coenzyme A, reduced nicotinamide adenine dinucleotide, and adenosine 5′-triphosphate, inducing gluconeogenesis (73). Acetyl-coenzyme A can leave the cell, becoming malonyl-coenzyme A, activating protein kinase C that in turn inhibits insulin signaling (59, 74, 75). High levels of free fatty acids are observed in burns (76, 77), possibly contributing to the insulin resistance observed in these patients. Although intracellular glucose oxidation has been reported to be normal in trauma patients (30, 78), our group demonstrated that mitochondrial oxidative function is impaired in burned children by 50% to 70% at 1 week after burn, persisting up to 3 to 4 weeks postburn (59, 79). Furthermore, a recent study by Vanhorebeek et al. (80) has confirmed mitochondrial dysfunction induced by hyperglycemia in an animal burn model. Maximal-coupled mitochondrial oxidative capacity has also been shown to be severely impaired after burns, with energy production likely wasted through uncoupling (79). Improving mitochondrial function may therefore be a potential treatment target for improving insulin sensitivity, as described in patients with type 2 diabetes (81).

After the acute phase of severe burn injury, patients remain in an extreme hypermetabolic and catabolic state, with resting metabolic rate known to increase by almost 100%. This condition was in the past believed to resolve with wound closure but has been proven to last for over a year after the time of injury (4, 5) together with elevation of counterregulatory hormones that may perpetuate hyperglycemia. Our group has found that hyperglycemia in burned patients persists for 6 months after injury but that insulin resistance may be observed for up to 3 years after burn (82). The severity of this metabolic state has a length unique to burned patients (5).

In summary, SIH after severe burns is a complex, multifactorial condition that results from a combination of factors leading to increased glucose production and reduced uptake and clearance, with features that may persist for years after initial injury. The long-term clinical relevance of SIH in burn patients is yet to be defined.


Hyperglycemia was considered a desired condition in critically ill patients, but recent evidence suggests significant deleterious effects of hyperglycemia. Critically ill patients with hyperglycemia have a higher incidence of infections and sepsis in both adult and pediatric populations (10, 39, 83). In burns, patients with poor glucose control have shown poorer outcomes (17), and glucose levels higher than 200 mg/dL have been associated with a significant risk of infectious complications, especially wound infections, pneumonia, and bacteremia. A glucose level greater than 140 mg/dL seems to heighten the clinical suspicion for the presence of an infection in patients with burn injury (18).

Is hyperglycemia deleterious? Evidence indicates that hyperglycemia causes glycosylation of proteins and that immunoglobulin G is inactivated when glycosylated (84); it causes suppression of IL-2 and IL-10 (85) and impairs macrophage and neutrophil function. This may explain the increased incidence of infections and sepsis found in the presence of hyperglycemia. In this respect, Gore et al. (13) found similar infection rates and hospital length of stay in burned children with poor glucose control and those with good glucose control; however, they also found a statistically greater frequency of fungemia in those patients deemed hyperglycemic. Hyperglycemia has also been shown to impair wound healing by decreasing tensile wound strength (86), with reduced graft take in burned patients with hyperglycemia compared with those with adequate glucose control (13, 87).

The extent of the burn surface area has not been shown to correlate to mean glucose levels (17, 88), but our group has found that insulin levels were significantly increased in after more than 80% total body surface area burns (4). Lower levels of insulin were also observed after smaller burns, indicating that with increasing severity of burn injury, insulin resistance may increase, and more insulin needs to be synthesized to maintain normoglycemia (4).

By studying the relationship between glucose levels and mortality, it has been suggested that admission glucose levels may be a better marker for the overall initial severity of illness of the patient (9, 63, 89-91), whereas mean glucose may predict overall mortality more closely (9).

Clinical trials on hyperglycemia treatment in burned patients

The ideal target of plasma glucose to improve clinical outcome has not been determined. Van den Berghe et al. (20) in their study showed a reduction in mortality by maintaining plasma glucose levels less than 110 mg/dL. Holm et al. (17) also reported improved survival when maintaining glucose in the range of 180 to 200 mg/dL, whereas others have suggested 120 mg/dL (18), 140 mg/dL (92), or 150 mg/dL (93) as a desired level. The recently published Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE-SUGAR) study has assessed glucose targets using intensive insulin control (4.5-6.0 mmol/L, 81-108 mg/dL) versus conventional insulin control (8.0-10.0 mmol/L, 144-180 mg/dL) in more than 6000 patients and reported lower mortality in the conventional group (94, 95). Tables 1 and 2 provide a brief summary of clinical trials that have assessed the effects of insulin treatment in burned and mixed or nonburned patients, with varying target glucose levels.

Table 1
Table 1:
Compilation of studies on burned patients describing the morbidity and mortality according to the target plasma glucose levels (PGL)
Table 2
Table 2:
Compilation of studies on trauma and nontrauma patients describing the morbidity and mortality according to the target plasma glucose levels (PGL)

Adequate control of hyperglycemia is not simple to achieve in burned patients: infusion of insulin when glucose levels exceeded 215 mg/dL was unsuccessful in controlling hyperglycemia in 27% of the patients in the first 48 h after burn in one study (17). Pediatric burn patients with glucose levels more than 200 mg/dL (11.1 mM/L) have been found to have poorer outcomes (13). Treatment of SIH in burned patients requires intensive insulin treatment and strict blood glucose control to overcome insulin resistance and also increases the risk of hypoglycemia (20). Intensive insulin treatment has increased severe hypoglycemic events, with incidence rates varying from 1.8% to 30%, depending on the target glucose level (96-98). Specifically in burned population, intensive insulin treatment has been shown to have either similar (18) or higher (99) rates of hypoglycemic events compared with conventional treatment. It is currently unclear whether hypoglycemia is associated with increased mortality or severe complications (i.e., seizures or death) (100). It is important to note that severely burned patients may have a potentially higher risk of hypoglycemic events due to the requirement for frequent surgeries, daily dressing changes, and tub room visits, which also necessitate stopping of enteral feeding and can induce altered intestinal motility (2).

We should note that insulin has a wide range of effects beyond increasing cellular glucose uptake (101, 102): it has both direct and indirect immune-modulatory effects; it causes a trophic effect on mucosal and skin barriers, protecting against bacterial invasion and translocation, thus potentially decreasing infection rates (103); and it improves wound matrix formation, therefore improving wound healing (104) as well as inhibiting the production of proinflammatory mediators (105-107) such as nuclear factor kappa B and I kappa B (108) and IL-5 and IL-6 (109).

A logical question arises as to whether the beneficial effects observed with insulin treatment are the effect of glucose modulation or is insulin per se responsible for them. Supporting the first premise, the hyperglycemic effects of glucose over time are known to be toxic (110, 111). Findings in surgical critically ill patients include that death rate is correlated with the degree of hyperglycemia (for a blood glucose level of 200 mg/dL, the risk of death was found to be 2.5 times higher than for a blood glucose level of 100 mg/dL). In addition, analysis of the observed protective effects of intensive insulin therapy on morbidity and mortality has been correlated with normalizing glucose levels rather than with the amount of infused insulin (21, 92).

To test the second premise and the direct effects of insulin, a logical approach may be to use alternative drugs that cause the desired effect of decreasing plasma glucose levels, comparing the observed morbidity and mortality with expectant care and insulin treatment in a prospective, randomized, and controlled protocol.

Metformin is a biguanide that effectively decreases glucose levels by improving insulin sensitivity, apparently centrally mediated (112), decreasing hepatic gluconeogenesis as much as 75% (113, 114) and has rarely been associated with hypoglycemia (5, 115). Instead, it has been associated with lactic acidosis (113), being contraindicated in hepatic or renal failure, conditions that can impair lactate clearance (116). Although a case report of metformin-related lactic acidosis in a burned patient has been published (116), in a review of trials evaluating metformin with more than 36,000 patients studied, not a single case of lactic acidosis was found (117), indicating the low incidence of this complication when used appropriately.

Metformin not only decreases glucose levels and improves glucose clearance but also increases the fractional synthetic rate of muscle protein and improves net muscle protein balance (112, 118, 119), theoretically improving glucose uptake. Gore et al. (118) performed a randomized study in burned patients comparing metformin with placebo and described a higher mortality in control patients (40%) than metformin-treated patients (20%).

Peroxisome proliferator-activated receptor α agonists, such as fenofibrate, improve insulin sensitivity by improving insulin receptor signaling (increasing tyrosine phosphorylation of insulin receptor and insulin receptor substrate 1) (59) as well as by suppression of peripheral lipolysis and redistribution of triglyceride stores to subcutaneous fat cells (59). In a double-blind, prospective, placebo-controlled, randomized trial with burned children, fenofibrate significantly improved insulin sensitivity, insulin signaling, and mitochondrial glucose oxidation (59) that can lead to a better management of SIH in burned patients (Fig. 3).

Fig. 3
Fig. 3:
Actions of metformin and fenofibrate. Burn patients typically display impaired insulin signaling, (which decreases insulin uptake by cells) and impaired mitochondrial oxidation. Metformin acts by decreasing hepatic gluconeogenesis and improving insulin sensitivity. Fenofibrate attenuates insulin resistance by acting on insulin signaling as well as increasing mitochondrial oxidation of intracellular glucose.

Unfortunately, however, improved management of hyperglycemia has not been adequate with metformin or fenofibrate alone, with the addition of insulin needed to achieve the target glucose levels cited in the protocols and making it difficult to categorically conclude if insulin or glucose modulation is responsible for the effects in burned patients.


Stress-induced hyperglycemia is a multifactorial condition and is a complex process in severely burned patients. The incidence and the prevalence of hyperglycemia in burned patients are difficult to determine, and this review has found that at present, there is as yet no consensus on a glucose level that defines hyperglycemia or a safe target glucose range for treatment in burned patients. It should be taken into consideration that by defining hyperglycemia at a level higher than 110 mg/dL, which is the consensus in other patients, it would imply that higher glucose levels are normal or acceptable in burned patients. The glucose level used to define hyperglycemia does not necessarily have to be the same as the target glucose range used for therapy.

The studies described in this article have found an increased incidence of fungemia, bacterial infections, and sepsis in hyperglycemic patients. These conditions themselves can produce or perpetuate hyperglycemia, indicating that hyperglycemia may also be a marker of sepsis rather than a direct cause. The fact that diabetic patients have an increased incidence of infection and that impairment occurs of immune cells, immunoglobulins, and inflammatory mediators in vitro when exposed to high glucose levels (84, 85) supports the role of hyperglycemia in increasing the incidence of infection. Furthermore, by treating hyperglycemia, infection rates are decreased, resulting in a beneficial impact on mortality, as infection and sepsis are major causes of death in severely burned patients (13, 120). Length of stay has also been found to be increased in critically ill patients with hyperglycemia (9), although this has not been found specifically among burned patients (13, 18, 99).

Insulin has both anabolic and anti-inflammatory effects as previously described, making it unlikely that the beneficial effects observed with intensive insulin treatment result only from normalization of glucose levels, being rather the combination of both glucose modulation and insulin action to some degree.

Interesting findings from a recent study in healthy individuals reported the effect of insulin after glucose ingestion and indicated that some humans are selectively resistant to insulin's suppression of proteolysis whereas others to insulin's suppression of lipolysis, which potentially leads to an "insulin response profile" (55). This finding may provide an explanation of the different responses to insulin observed even within the same study (112).

Regarding cytokines and ILs, although IL-6 is elevated in burned patients, it has not been found to be a contributor to acute hyperglycemia induced by stress (121). Similarly, IL-1 has not been associated with hyperglycemia in burn patients. In fact, it has been described that an IL-1β-secreting tumor increased glucose uptake and decreased hepatic gluconeogenesis, leading to the development of hypoglycemia (122). In addition, hyperglycemia itself may lead to an increased concentration of circulating cytokines, including IL-6 (123).

In the NICE-SUGAR study, survival was found to be better in the conventional group, but further analysis of the odds ratio for death (95% confidence interval) resulted in better outcome within the trauma subpopulation with intensive insulin treatment (95). Unfortunately, it was not described if burn patients were included in the study.

The utility of alternative anti-hyperglycemic drugs to decrease the incidence of hypoglycemic events observed with insulin is still under study. The decreased mortality rates described by Gore et al. (118) using metformin in burned patients, which included only five patients per group, included a death in the placebo group secondary to dislodgement of an endotracheal tube, making it difficult to achieve a conclusion in this study. The literature on the use of metformin in burned patients remains scarce.

It is likely that decreasing glucose levels with intensive insulin therapy may be beneficial in critically ill patients, but the current evidence is not decisive, especially for burned patients. Although the available studies have shown improved survival with lower glucose levels, the studied population is small, with the studies being either retrospective or not controlled. It is yet to be determined whether insulin or euglycemia would be responsible for the mentioned effects.

A table of up-to-date clinical trials studying hyperglycemia in burned patients (Table 1) has been compiled, but based on this review, we can conclude that an ideal target range for glucose levels in burned patients is still to be determined.


With recent multicenter trials indicating potential harm from intensive insulin treatment whereas others indicate beneficial outcomes, the future of tight glycemic control remains intriguing. Several key questions remain to be addressed, for example, which patient population is tight euglycemic control most beneficial? Current evidence indicates possible advantages in the use of intensive insulin regimens during the acute management of trauma patients (20-22, 99) recently confirmed in a subanalysis of the published NICE-SUGAR trial (95).

In severely burned patients, effects and implications of euglycemic control after injury remain to be determined, and groups including our own are currently conducting trials to clarify this issue. Another important factor for this population would be to determine an effective yet safe glucose range for optimal outcomes.

Debate also persists as to whether the findings described arise due to insulin treatment, from modulation of glucose levels, or a combined effect. Newer generations of anti-hyperglycemic drugs may help to clarify whether glucose modulation leads to the suggested benefits. These include the peroxisome proliferator-activated receptor modulators fenofibrate and glitazones as well as the glucagon-like peptide 1 and its analogs and dipeptidyl peptidase 4 inhibitors. However, the role and the efficacy of these agents in the trauma and burn care setting are yet to be evaluated.

The duration of hyperglycemia and altered insulin sensitivity after burn injury is a recent finding made by our group. Hyperglycemia was shown to persist for 6 months, whereas insulin sensitivity remained disturbed for a striking duration of up to 3 years postburn (82). Long-term follow-up studies would be useful in assessing the clinical impact of the prolonged disturbance in glucose kinetics in burn survivors. This would also help to determine whether patients may benefit from interventions to treat altered insulin sensitivity and glucose kinetics after discharge.

We suggest that an evidence-based consensus is needed on an appropriate and safe target range for glucose levels during acute burn care. A multicenter study may be required to accomplish this to enroll the number of patients required to reach an unequivocal conclusion. Controversy and debate are welcome and when tackled constructively lead to progress through innovation and novel approaches and result in enhanced treatment strategies and patient care.


Although most burn centers may be implementing intensive insulin practices, the available literature fails to unequivocally confirm superior risk-benefit ratio of intensive insulin treatment in these patients. Severely burned patients represent the most critical trauma model, necessitating prospective, randomized, and controlled studies to assess the impact of hyperglycemia and its treatment specifically in burned patients. It is likely that multicenter studies will be needed to collect enough information to be able to produce a consensus that will determine the paradigm of treatment of hyperglycemia in burned patients.


1. Demling RH: Burns: what are the pharmacological treatment options. Expert Opin Pharmacother 9(11):1895-1908, 2008.
2. Herndon DN, Tompkins RG: Support of the metabolic response to burn injury. Lancet 363(9424):1895-1902, 2004.
3. American Burn Association/American College of Surgeons: Guidelines for the operation of burn centers. J Burn Care Res 28(1):134-141, 2007.
4. Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, Norbury WB, Branski LK, Gauglitz GG, Mlcak RP, Herndon DN: Pathophysiologic response to severe burn injury. Ann Surg 248(3):387-401, 2008.
5. Gauglitz GG, Herndon DN, Jeschke MG: Insulin resistance postburn: underlying mechanisms and current therapeutic strategies. J Burn Care Res 29(5):683-694, 2008.
6. Bernard C: Leçons sur les phénomènes de la vie communs aux animaux et aux végétaux. 2 Tomes. Edité par Albert Dastre. Paris, France: Baillière et Fils, 1878.
7. Toschlog EA, Newton C, Allen N, Newell MA, Goettler CE, Schenarts PJ, Bard MR, Sagraves SG, Rotondo MF: Morbidity reduction in critically ill trauma patients through use of a computerized insulin infusion protocol: a preliminary study. J Trauma 62(6):1370-1375, 2007; discussion 1375-1376.
8. Goodall M, Stone C, Haynes BW Jr: Urinary output of adrenaline and noradrenaline in severe thermal burns. Ann Surg 145(4):479-487, 1957.
9. Wahl WL, Taddonio M, Maggio PM, Arbabi S, Hemmila MR: Mean glucose values predict trauma patient mortality. J Trauma 65(1):42-47, 2008; discussion 47-48.
10. McCowen KC, Malhotra A, Bistrian BR: Stress-induced hyperglycemia. Crit Care Clin 17(1):107-124, 2001.
11. Hart DW, Wolf SE, Chinkes DL, Gore DC, Mlcak RP, Beauford RB, Obeng MK, Lal S, Gold WF, Wolfe RR, et al.: Determinants of skeletal muscle catabolism after severe burn. Ann Surg 232(4):455-465, 2000.
12. Jeschke MG, Chinkes DL, Finnerty CC, Przkora R, Pereira CT, Herndon DN: Blood transfusions are associated with increased risk for development of sepsis in severely burned pediatric patients. Crit Care Med 35(2):579-583, 2007.
13. Gore DC, Chinkes D, Heggers J, Herndon DN, Wolf SE, Desai M: Association of hyperglycemia with increased mortality after severe burn injury. J Trauma 51(3):540-544, 2001.
14. Gelfand RA, Matthews DE, Bier DM, Sherwin RS: Role of counterregulatory hormones in the catabolic response to stress. J Clin Invest 74(6):2238-2248, 1984.
15. Losser MR, Bernard C, Beaudeux JL, Pison C, Payen D: Glucose modulates hemodynamic, metabolic, and inflammatory responses to lipopolysaccharide in rabbits. J Appl Physiol 83(5):1566-1574, 1997.
16. Wilmore DW: Carbohydrate metabolism in trauma. Clin Endocrinol Metab 5(3):731-745, 1976.
17. Holm C, Horbrand F, Mayr M, von Donnersmarck GH, Muhlbauer W: Acute hyperglycaemia following thermal injury: friend or foe? Resuscitation 60(1):71-77, 2004.
18. Hemmila MR, Taddonio MA, Arbabi S, Maggio PM, Wahl WL: Intensive insulin therapy is associated with reduced infectious complications in burn patients. Surgery 144(4):629-635, 2008; discussion 635-637.
19. Chatham JC, Not LG, Fulop N, Marchase RB: Hexosamine biosynthesis and protein O-glycosylation: the first line of defense against stress, ischemia, and trauma. Shock 29(4):431-440, 2008.
20. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345(19):1359-1367, 2001.
21. Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31(2):359-366, 2003.
22. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, VanWijngaerden E, Bobbaers H, Bouillon R: Intensive insulin therapy in the medical ICU. N Engl J Med 354(5):449-461, 2006.
23. Merz TM, Finfer S: Intensive insulin treatment. Minerva Anestesiol [Epub ahead of print] 2009.
24. Mann EA, Pidcoke HF, Salinas J, Holcomb JB, Wolf SE, Wade CE: The impact of intensive insulin protocols and restrictive blood transfusion strategies on glucose measurement in American Burn Association (ABA) verified burn centers. J Burn Care Res 29(5):718-723, 2008.
25. Tredget EE, Yu YM: The metabolic effects of thermal injury. World J Surg 16(1):68-79, 1992.
26. Finnerty CC, Herndon DN, Przkora R, Pereira CT, Oliveira HM, Queiroz DM, Rocha AM, Jeschke MG: Cytokine expression profile over time in severely burned pediatric patients. Shock 26(1):13-19, 2006.
27. Turina M, Christ-Crain M, Polk HC Jr: Diabetes and hyperglycemia: strict glycemic control. Crit Care Med 34(9 suppl):S291-S300, 2006.
28. Jeschke MG, Micak RP, Finnerty CC, Herndon DN: Changes in liver function and size after a severe thermal injury. Shock 28(2):172-177, 2007.
29. Yu CC, Hua HA, Tong C: Hyperglycaemia after burn injury. Burns 15(3):145-146, 1989.
30. Wolfe RR, Jahoor F, Herndon DN, Miyoshi H: Isotopic evaluation of the metabolism of pyruvate and related substrates in normal adult volunteers and severely burned children: effect of dichloroacetate and glucose infusion. Surgery 110(1):54-67, 1991.
31. Padfield KE, Astrakas LG, Zhang Q, Gopalan S, Dai G, Mindrinos MN, Tompkins RG, Rahme LG, Tzika AA: Burn injury causes mitochondrial dysfunction in skeletal muscle. Proc Natl Acad Sci U S A 102(15):5368-5373, 2005.
32. Lee K, Berthiaume F, Stephanopoulos GN, Yarmush ML: Profiling of dynamic changes in hypermetabolic livers. Biotechnol Bioeng 83(4):400-415, 2003.
33. Harrison TS, Seaton JF, Feller I: Relationship of increased oxygen consumption to catecholamine excretion in thermal burns. Ann Surg 165(2):169-172, 1967.
34. Goodall MC, Alton H: Dopamine (3-hydroxytyramine) replacement and metabolism in sympathetic nerve and adrenal medullary depletions after prolonged thermal injury. J Clin Invest 48(9):1761-1767, 1969.
35. Wolfe RR: Herman Award Lecture, 1996: relation of metabolic studies to clinical nutrition-the example of burn injury. Am J Clin Nutr 64(5):800-808, 1996.
36. Vaughan GM, Becker RA, Unger RH, Ziegler MG, Siler-Khodr TM, Pruitt BA Jr, Mason AD Jr: Nonthyroidal control of metabolism after burn injury: possible role of glucagon. Metabolism 34(7):637-641, 1985.
37. Lee SM, Clemens MG: Glucagon increases gap junctional intercellular communication via cAMP in the isolated perfused rat liver. Shock 22(1):82-87, 2004.
38. Jahoor F, Herndon DN, Wolfe RR: Role of insulin and glucagon in the response of glucose and alanine kinetics in burn-injured patients. J Clin Invest 78(3):807-814, 1986.
39. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341(11):785-792, 1999.
40. Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 77(6):1690-1694, 1993.
41. Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130(1):43-52, 1992.
42. Akita S, Akino K, Ren SG, Melmed S, Imaizumi T, Hirano A: Elevated circulating leukemia inhibitory factor in patients with extensive burns. J Burn Care Res 27(2):221-225, 2006.
43. Heise T, Heinemann L, Starke AA: Simulated postaggression metabolism in healthy subjects: metabolic changes and insulin resistance. Metabolism 47(10):1263-1268, 1998.
44. Spitzer JJ, Bagby GJ, Meszaros K, Lang CH: Altered control of carbohydrate metabolism in endotoxemia. Prog Clin Biol Res 286:145-165, 1989.
45. Shamoon H, Hendler R, Sherwin RS: Synergistic interactions among antiinsulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab 52(6):1235-1241, 1981.
46. Walker PS, Ramlal T, Sarabi V, Koivisto UM, Bilan PJ, Pessin JE, Klip A: Glucose transport activity in L6 muscle cells is regulated by the coordinate control of subcellular glucose transporter distribution, biosynthesis, and mRNA transcription. J Biol Chem 265(3):1516-1523, 1990.
47. D'Angelica M, Yuman Fong M: In Townsend CM, Beauchamp RD, Evers BM, Mattox KL, eds. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 18th ed. Philadelphia, Pa: Saunders/Elsevier; 2007:997-1056.
48. Gammeltoft S, Van Obberghen E: Protein kinase activity of the insulin receptor. Biochem J 235(1):1-11, 1986.
49. Cree MG, Aarsland A, Herndon DN, Wolfe RR: Role of fat metabolism in burn trauma-induced skeletal muscle insulin resistance. Crit Care Med 35(9 suppl):S476-S483, 2007.
50. Stadie WC, Haugaard N, Vaughan M: The quantitative relation between insulin and its biological activity. J Biol Chem 200(2):745-751, 1953.
51. Chernick SS, Chaikoff IL: Insulin and hepatic utilization of glucose for lipogenesis. J Biol Chem 186(2):535-542, 1950.
52. Martin BR, Denton RM, Pask HT, Randle PJ: Mechanisms regulating adipose-tissue pyruvate dehydrogenase. Biochem J 129(3):763-773, 1972.
53. Navarro P, Valverde AM, Benito M, Lorenzo M: Insulin/IGF-I rescues immortalized brown adipocytes from apoptosis down-regulating Bcl-xS expression, in a PI 3-kinase- and map kinase-dependent manner. Exp Cell Res 243(2):213-221, 1998.
54. Flakoll PJ, Hill JO, Abumrad NN: Acute hyperglycemia enhances proteolysis in normal man. Am J Physiol 265(5 Pt 1):E715-E721, 1993.
55. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, Carr SA, Thadhani R, Gerszten RE, Mootha VK: Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 4:214, 2008.
56. Gore DC, Chinkes DL, Hart DW, Wolf SE, Herndon DN, Sanford AP: Hyperglycemia exacerbates muscle protein catabolism in burn-injured patients. Crit Care Med 30(11):2438-2442, 2002.
57. Little RA, Henderson A, Frayn KN, Galasko CS, White RH: The disposal of intravenous glucose studied using glucose and insulin clamp techniques in sepsis and trauma in man. Acta Anaesthesiol Belg 38(4):275-279, 1987.
58. Black PR, Brooks DC, Bessey PQ, Wolfe RR, Wilmore DW: Mechanisms of insulin resistance following injury. Ann Surg 196(4):420-435, 1982.
59. Cree MG, Zwetsloot JJ, Herndon DN, Qian T, Morio B, Fram R, Sanford AP, Aarsland A, Wolfe RR: Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg 245(2):214-221, 2007.
60. Carter EA, Burks D, Fischman AJ, White M, Tompkins RG: Insulin resistance in thermally-injured rats is associated with post-receptor alterations in skeletal muscle, liver and adipose tissue. Int J Mol Med 14(4):653-658, 2004.
61. Ikezu T, Okamoto T, Yonezawa K, Tompkins RG, Martyn JA: Analysis of thermal injury-induced insulin resistance in rodents. Implication of postreceptor mechanisms. J Biol Chem 272(40):25289-25295, 1997.
62. Kasper SO, Castle SM, Daley BJ, Enderson BL, Karlstad MD: Blockade of the renin-angiotensin system improves insulin sensitivity in thermal injury. Shock 26(5):485-488, 2006.
63. Shin S, Britt RC, Reed SF, Collins J, Weireter LJ, Britt LD: Early glucose normalization does not improve outcome in the critically ill trauma population. Am Surg 73(8):769-772, 2007; discussion 772.
64. Schenk S, Saberi M, Olefsky JM: Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118(9):2992-3002, 2008.
65. Lim JH, Lee HJ, Ho Jung M, Song J: Coupling mitochondrial dysfunction to endoplasmic reticulum stress response: A molecular mechanism leading to hepatic insulin resistance. Cell Signal 21(1):169-177, 2008.
66. Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka TA, Matsuhisa M, Yamasaki Y: Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic beta-cell dysfunction and insulin resistance. Int J Biochem Cell Biol 38(5-6):782-793, 2006.
67. Deng J, Wang G, Huang Q, Yan Y, Li K, Tan W, Jin C, Wang Y, Liu J: Oxidative stress-induced leaky sarcoplasmic reticulum underlying acute heart failure in severe burn trauma. Free Radic Biol Med 44(3):375-385, 2008.
68. Murphy JT, Giroir B, Horton JW: Thermal injury alters myocardial sarcoplasmic reticulum calcium channel function. J Surg Res 82(2):244-252, 1999.
69. Gauglitz GG, Song J, Herndon DN, Finnerty CC, Boehning DF, Barral JM, Jeschke MG: Characterization of the inflammatory response during acute and postacute phases after severe burn. Shock 30(5):503-507, 2008.
70. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 115(5):1111-1119, 2005.
71. Aguirre V, Uchida T, Yenush L, Davis R, White MF: The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275(12):9047-9054, 2000.
72. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306(5695):457-461, 2004.
73. Delarue J, Magnan C: Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 10(2):142-148, 2007.
74. Koh EH, Lee WJ, Kim MS, Park JY, Lee IK, Lee KU: Intracellular Fatty Acid metabolism in skeletal muscle and insulin resistance. Curr Diabetes Rev 1(3):331-336, 2005.
75. Randle PJ: Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14(4):263-283, 1998.
76. Li F, Guo ZR, Chai JK, Sheng Z: Effects of escharectomy during shock stage on the plasma lipid and serum free fatty acid levels in scalded rats. Zhonghua Shao Shang Za Zhi 19(4):206-208, 2003.
77. Cree MG, Zwetsloot JJ, Herndon DN, Newcomer BR, Fram RY, Angel C, Green JM, Dohm GL, Sun D, Aarsland A, et al.: Insulin sensitivity is related to fat oxidation and protein kinase C activity in children with acute burn injury. J Burn Care Res 29(4):585-594, 2008.
78. Jeevanandam M, Young DH, Schiller WR: Glucose turnover, oxidation, and indices of recycling in severely traumatized patients. J Trauma 30(5):582-589, 1990.
79. Cree MG, Fram RY, Herndon DN, Qian T, Angel C, Green JM, Mlcak R, Aarsland A, Wolfe RR: Human mitochondrial oxidative capacity is acutely impaired after burn trauma. Am J Surg 196(2):234-239, 2008.
80. Vanhorebeek I, Ellger B, De Vos R, Boussemaere M, Debaveye Y, Vander Perre S, Rabbani N, Thornalley PJ, Van den Berghe G: Tissue-specific glucose toxicity induces mitochondrial damage in a burn injury model of critical illness. Crit Care Med 37(4):1355-1364, 2009.
81. Kelley DE, He J, Menshikova EV, Ritov VB: Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51(10):2944-2950, 2002.
82. Gauglitz GG, Herndon DN, Kulp GA, Meyer WJ 3rd, Jeschke MG: Abnormal Insulin Sensitivity Persists up to Three Years in Pediatric Patients Post-Burn. J Clin Endocrinol Metab 94(5):1656-1664, 2009.
83. Tuggle DW, Kuhn MA, Jones SK, Garza JJ, Skinner S: Hyperglycemia and infections in pediatric trauma patients. Am Surg 74(3):195-198, 2008.
84. Black CT, Hennessey PJ, Andrassy RJ: Short-term hyperglycemia depresses immunity through nonenzymatic glycosylation of circulating immunoglobulin. J Trauma 30(7):830-832, 1990; discussion 832-833.
85. Reinhold D, Ansorge S, Schleicher ED: Elevated glucose levels stimulate transforming growth factor-beta 1 (TGF-beta 1), suppress interleukin IL-2, IL-6 and IL-10 production and DNA synthesis in peripheral blood mononuclear cells. Horm Metab Res 28(6):267-270, 1996.
86. Verhofstad MH, Hendriks T: Complete prevention of impaired anastomotic healing in diabetic rats requires preoperative blood glucose control. Br J Surg 83(12):1717-1721, 1996.
87. Mowlavi A, Andrews K, Milner S, Herndon DN, Heggers JP: The effects of hyperglycemia on skin graft survival in the burn patient. Ann Plast Surg 45(6):629-632, 2000.
88. Childs C, Heath DF, Little RA, Brotherston M: Glucose metabolism in children during the first day after burn injury. Arch Emerg Med 7(3):135-147, 1990.
89. Sung J, Bochicchio GV, Joshi M, Bochicchio K, Tracy K, Scalea TM: Admission hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma 59(1):80-83, 2005.
90. Bochicchio GV, Salzano L, Joshi M, Bochicchio K, Scalea TM: Admission preoperative glucose is predictive of morbidity and mortality in trauma patients who require immediate operative intervention. Am Surg 71(2):171-174, 2005.
91. Sperry JL, Frankel HL, Vanek SL, Nathens AB, Moore EE, Maier RV, Minei JP: Early hyperglycemia predicts multiple organ failure and mortality but not infection. J Trauma 63(3):487-493, 2007; discussion 493-494.
92. Finney SJ, Zekveld C, Elia A, Evans TW: Glucose control and mortality in critically ill patients. JAMA 290(15):2041-2047, 2003.
93. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(1):296-327, 2008.
94. The George Institute: Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation-NICE-SUGAR. 2007. Available at: Accessed: January 21, 2009.
95. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, et al.: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360(13):1283-1297, 2009.
96. Langouche L, Vanhorebeek I, Van den Berghe G: Therapy insight: the effect of tight glycemic control in acute illness. Nat Clin Pract Endocrinol Metab 3(3):270-278, 2007.
97. Krinsley JS: Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 79(8):992-1000, 2004.
98. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, et al.: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358(2):125-139, 2008.
99. Pham TN, Warren AJ, Phan HH, Molitor F, Greenhalgh DG, Palmieri TL: Impact of tight glycemic control in severely burned children. J Trauma 59(5):1148-1154, 2005.
100. Cochran A, Davis L, Morris SE, Saffle JR: Safety and efficacy of an intensive insulin protocol in a burn-trauma intensive care unit. J Burn Care Res 29(1):187-191, 2008.
101. Dugo L, Collin M, Thiemermann C: Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock 27(2):113-123, 2007.
102. de Oliveira Martins J, Meyer-Pflug AR, Alba-Loureiro TC, Melbostad H, Costa da Cruz JW, Coimbra R, Curi R, Sannomiya P: Modulation of lipopolysaccharide-induced acute lung inflammation: Role of insulin. Shock 25(3):260-266, 2006.
103. Wheeler EE, Challacombe DN: The trophic action of growth hormone, insulin-like growth factor-I, and insulin on human duodenal mucosa cultured in vitro. Gut 40(1):57-60, 1997.
104. Pierre EJ, Barrow RE, Hawkins HK, Nguyen TT, Sakurai Y, Desai M, Wolfe RR, Herndon DN: Effects of insulin on wound healing. J Trauma 44(2):342-345, 1998.
105. Ottlecz A, Koltai M, Blazso G, Minker E: Contribution to the regulatory role of insulin in inflammation and anaphylaxis. Int Arch Allergy Appl Immunol 56(3):284-286, 1978.
106. Burton JL, Elsasser TH, Rumsey TS, Lunney JK, McBride BW: Immune responses of growing beef steers treated with estrogen/progesterone implants or insulin injections. Domest Anim Endocrinol 10(1):31-44, 1993.
107. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G: Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88(3):1082-1088, 2003.
108. Cuschieri J, Bulger E, Grinsell R, Garcia I, Maier RV: Insulin regulates macrophage activation through activin A. Shock 29(2):285-290, 2008.
109. Przkora R, Herndon DN, Finnerty CC, Jeschke MG: Insulin attenuates the cytokine response in a burn wound infection model. Shock 27(2):205-208, 2007.
110. Porte D Jr, Schwartz MW: Diabetes complications: why is glucose potentially toxic? Science 272(5262):699-700, 1996.
111. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977-986, 1993.
112. Gore DC, Herndon DN, Wolfe RR: Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. J Trauma 59(2):316-322, 2005; discussion 322-323.
113. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333(9):550-554, 1995.
114. Wollen N, Bailey CJ: Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochem Pharmacol 37(22):4353-4358, 1988.
115. Gore DC, Wolf SE, Herndon DN, Wolfe RR: Relative influence of glucose and insulin on peripheral amino acid metabolism in severely burned patients. JPEN J Parenter Enteral Nutr 26(5):271-277, 2002.
116. Riesenman PJ, Braithwaite SS, Cairns BA: Metformin-associated lactic acidosis in a burn patient. J Burn Care Res 28(2):342-347, 2007.
117. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 163(21):2594-2602, 2003.
118. Gore DC, Wolf SE, Herndon DN, Wolfe RR: Metformin blunts stress-induced hyperglycemia after thermal injury. J Trauma 54(3):555-561, 2003.
119. Gore DC, Wolf SE, Sanford A, Herndon DN, Wolfe RR: Influence of metformin on glucose intolerance and muscle catabolism following severe burn injury. Ann Surg 241(2):334-342, 2005.
120. Song J, Wolf SE, Herndon DN, Wu XW, Jeschke MG: Second hit post burn increased proximal gut mucosa epithelial cells damage. Shock 30(2):184-188, 2008.
121. Nonogaki K, Iguchi A: Stress, acute hyperglycemia, and hyperlipidemia role of the autonomic nervous system and cytokines. Trends Endocrinol Metab 8(5):192-197, 1997.
122. Metzger S, Nusair S, Planer D, Barash V, Pappo O, Shilyansky J, Chajek-Shaul T: Inhibition of hepatic gluconeogenesis and enhanced glucose uptake contribute to the development of hypoglycemia in mice bearing interleukin-1beta- secreting tumor. Endocrinology 145(11):5150-5156, 2004.
123. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106(16):2067-2072, 2002.
124. Quinn JA, Snyder SL, Berghoff JL, Colombo CS, Jacobi J: A practical approach to hyperglycemia management in the intensive care unit evaluation of an intensive insulin infusion protocol. Pharmacotherapy 26(10):1410-1420, 2006.

Burns; intensive insulin; glucose modulation; metformin; fenofibrate

©2010The Shock Society